



CSL Behring – Withdrawal of Hizentra® [immune globulin subcutaneous (human)]

- On October 27, 2021, [CSL Behring announced](#) a patient-level withdrawal of one lot of [Hizentra \[immune globulin subcutaneous \(human\)\]](#) due to an increased frequency of reports of injection-site reactions and local hypersensitivity-type of events after administration.
- Other Hizentra products that are not being removed from the market are available for patients to use.
- The withdrawn lot was shipped from CSL Behring in September 2021.

Product Description	NDC	Lot # (Expiration Date)
Hizentra [immune globulin subcutaneous (human)] 20% liquid	44206-0455-10	P100340460 (11/12/2023)

- Hizentra is indicated for the treatment of primary immunodeficiency in adults and pediatric patients 2 years of age and older and for maintenance therapy in adults with chronic inflammatory demyelinating polyneuropathy.
- Injection-site reactions and hypersensitivity are a known risk with subcutaneous immune globulin products.
- Patients should contact their healthcare provider if they have experienced any problems that may be related to using the withdrawn Hizentra.
- Contact CSL Behring Medical Information by phone at **1-800-504-5434** or by email at **MedinfoNA@cslbehring.com** for more information about the withdrawal.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.